Literature DB >> 4639015

Structural and functional studies on hemoglobin Bethesda (alpha2beta2 145His), a varient associated with compensatory erythrocytosis.

H F Bunn, T B Bradley, W E Davis, J W Drysdale, J F Burke, W S Beck, M B Laver.   

Abstract

Studies have been performed on a 12-yr-old Chinese girl with compensatory erythrocytosis due to the presence of hemoglobin Bethesda comprising about 45% of the red cell hemoglobin. Her parents and three siblings were normal. The oxygen affinity of her blood was markedly increased: under physiological conditions (pH 7.40, 37 degrees C). P(50) was 12.8 mm Hg (normal = 26.5 mm Hg). The red cell 2,3-diphosphoglycerate (2.3-DPG) level was normal. The abnormal hemoglobin could not be separated from hemoglobin A by zone electrophoresis at pH 8.6 or isoelectric focusing on polyacrylamide gel. However, after the hemoglobin was split into free alpha and beta chains by treatment with p-hydroxymercuribenzoate (PMB) or 6 M urea, an abnormal beta chain was readily demonstrated having a higher isoelectric point (more positive net charge) than normal beta(A). Structural analysis of the variant beta chain demonstrated the substitution of histidine for tyrosine at position 145: hemoglobin Bethesda (alpha(2)beta(2) (145His)). From earlier chemical and crystallographic studies, it has been postulated that this residue is a critical determinant of hemoglobin function. Hemoglobin Bethesda was separated from hemoglobin A by column chromatography. Oxygen equilibria of purified hemoglobin Bethesda revealed an extremely high oxygen affinity (exceeding that of isolated alpha and beta chains), and markedly reduced cooperativity. The Bohr effect of hemoglobin Bethesda was 1/3 that of hemoglobin A. However, hemoglobin Bethesda showed a significant interaction with 2.3-DPG and inositol hexaphosphate.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4639015      PMCID: PMC292395          DOI: 10.1172/JCI107040

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Haemoglobin M Hyde Park: a hereditary methaemoglobinaemia in a Caucasian child.

Authors:  D M Becroft; R Douglas; R W Carrell; H Lehmann
Journal:  N Z Med J       Date:  1968-08

2.  Haemoglobin Hammersmith (beta-42 (CDI) Phe replaced by ser).

Authors:  J V Dacie; N K Shinton; P J Gaffney; H Lehmann
Journal:  Nature       Date:  1967-11-18       Impact factor: 49.962

3.  Evidence suggesting a non-random character to nucleotide replacements in naturally occurring mutations.

Authors:  W M Fitch
Journal:  J Mol Biol       Date:  1967-06-28       Impact factor: 5.469

4.  Blood gas calculator.

Authors:  J W Severinghaus
Journal:  J Appl Physiol       Date:  1966-05       Impact factor: 3.531

5.  Polycythemia associated with a hemoglobinopathy.

Authors:  S Charache; D J Weatherall; J B Clegg
Journal:  J Clin Invest       Date:  1966-06       Impact factor: 14.808

6.  Hemoglobin Gun Hill: deletion of five amino acid residues and impaired heme-globin binding.

Authors:  T B Bradley; R C Wohl; R F Rieder
Journal:  Science       Date:  1967-09-29       Impact factor: 47.728

7.  Relation between structure and function in Hemoglobin Chesapeake.

Authors:  R L Nagel; Q H Gibson; S Charache
Journal:  Biochemistry       Date:  1967-08       Impact factor: 3.162

8.  Abnormal human haemoglobins. Separation and characterization of the alpha and beta chains by chromatography, and the determination of two new variants, hb Chesapeak and hb J (Bangkok).

Authors:  J B Clegg; M A Naughton; D J Weatherball
Journal:  J Mol Biol       Date:  1966-08       Impact factor: 5.469

9.  Hemoglobin Yakina. II. High blood oxygen affinity associated with compensatory erythrocytosis and normal hemodynamics.

Authors:  M J Novy; M J Edwards; J Metcalfe
Journal:  J Clin Invest       Date:  1967-11       Impact factor: 14.808

10.  Hemoglobin Freiburg: abnormal hemoglobin due to deletion of a single amino acid residue.

Authors:  R T Jones; B Brimhall; T H Huisman; E Kleihauer; K Betke
Journal:  Science       Date:  1966-11-25       Impact factor: 47.728

View more
  8 in total

1.  Structure-function relations of human hemoglobins.

Authors:  Alain J Marengo-Rowe
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-07

2.  Camptodactyly, with muscular hypoplasia, skeletal dysplasia, and abnormal palmar creases: Tel Hashomer camptodactyly syndrome.

Authors:  R M Goodman; M B Katznelson; M Hertz; A Katznelson
Journal:  J Med Genet       Date:  1976-04       Impact factor: 6.318

3.  Haemoglobin M Hyde Park occurring as a fresh mutation: diagnostic, structural, and genetic considerations.

Authors:  G Stamatoyannopoulos; P E Nute; E Giblett; J Detter; R Chard
Journal:  J Med Genet       Date:  1976-04       Impact factor: 6.318

4.  De novo mutations producing unstable Hbs or Hbs M. II. Direct estimates of minimum nucleotide mutation rates in man.

Authors:  G Stamatoyannopoulos; P E Nute
Journal:  Hum Genet       Date:  1982       Impact factor: 4.132

5.  Hemoglobin Syracuse (alpha2beta2-143(H21)His leads to Pro), a new high-affinity variant detected by special electrophoretic methods. Observations on the auto-oxidation of normal and variant hemoglobins.

Authors:  M Jensen; F A Oski; D G Nathan; H F Bunn
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

6.  De novo mutations producing unstable hemoglobins or hemoglobins M : I. Establishment of a Depository and use of data to test for an association of de novo mutation with advanced parental age.

Authors:  G Stamatoyannopoulos; P E Nute; M Miller
Journal:  Hum Genet       Date:  1981-10       Impact factor: 4.132

7.  Hemoglobin McKees Rocks (alpha2beta2145Tyr leads to Term). A human "nonsense" mutation leading to a shortened beta-chain.

Authors:  R M Winslow; M L Swenberg; E Gross; P A Chervenick; R R Buchman; W F Anderson
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

8.  Hemoglobin brigham (alpha2Abeta2100 Pro--Leu). Hemoglobin variant associated with familial erythrocytosis.

Authors:  J J Lokich; W C Moloney; H F Bunn; S M Bruckheimer; H M Ranney
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.